onkoserv

Substanz: Trastuzumab

zurück

2012

Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer

Cancer 118 (2012) 4936-4943

Pegylated liposomal doxorubicin plus carboplatin in patients with metastatic breast cancer: a phase II study

Ann Oncol 23 (2012) 2599-2605

Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

J Clin Oncol 30 (2012) online first 17. 9. 2012

Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study

JNCI (2012) Online first (= Link zum PDF-Volltext)

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

Lancet Oncol 13 (2012) 869-878

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study

J Clin Oncol 30 (2012) 1989-1995

Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence

Breast Cancer Res Treatm 135 (2012) Online first 9. 8. 2012

Outcomes of women with early-stage breast cancer receiving adjuvant trastuzumab

Curr Oncol 19 (2012) 197-201

Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer

Oncologist 17 (2012) 469-475

Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2

Anti-Cancer Drugs 23 (2012) 239-246

Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study

J Clin Oncol 30 (2012) Online first 11. 6. 2012

Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01)

Breast Cancer Res Treat 133 (2012) 387-391

Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

J Clin Oncol 30 (2012) 1594-1600

Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines - a phase II multipractice study

BMC Cancer 12 (2012) 165

Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer

Cancer 118 (2012) 2385-2393

Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer

Cancer 118 (2012) 1982-1988

Phase II Interventional Study (N0337) of Capecitabine in Combination With Vinorelbine and Trastuzumab for First- or Second-Line Treatment of HER2-Positive Metastatic Breast Cancer: A North Central Cancer Treatment Group Trial

Clin Breast Cancer 12 (2012) 81-86

Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors

Ann Oncol 23 (2012) 897-902

Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer

Br J Cancer 106 (2012) 1033-1038

Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study

Blood 119 (2012) 2474-2477